Who is the manufacturer of bosutinib/bosutinib?

Bosutinib/Bosutinib, trade name Bosulif, is a small molecule targeted drug mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The drug's mechanism of action is by inhibiting BCR-ABL and src tyrosine kinase, thereby effectively preventing the growth and spread of cancer cells. Development of bosutinib began at Wyeth Pharmaceuticals and was subsequently acquired and developed by Pfizer.

Wyeth originally played an important role in the synthesis and early research of bosutinib. As the drug entered the clinical approval stage, Pfizer acquired Wyeth in 2009 and became the primary developer and commercializer of bosutinib. Driven by Pfizer, bosutinib was approved by the U.S. Food and Drug Administration (FDA) in 2012 and was officially launched for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic and accelerated phases.

As a leading global pharmaceutical company, Pfizer has extensive experience and resources in drug research and development, production and marketing. The launch of bosutinib not only provides a new treatment option for patients with chronic myelogenous leukemia, but also lays the foundation for Pfizer to further expand its product line in the field of oncology. Pfizer actively promotes bosutinib globally and participates in multiple clinical studies to evaluate its efficacy and safety in different patient populations.

In addition to the effectiveness of bosutinib, Pfizer is also focusing on the management of the drug's side effects and providing relevant support in clinical practice. This series of efforts has enabled bosutinib to gain a good reputation in the treatment of chronic myelogenous leukemia, especially in patients who are resistant or intolerant to previous treatments, showing its unique advantages.

Reference materials:https://bosulif.pfizerpro.com/